EGFR and non-small cell lung carcinoma: EMT is characterized by histological changes in a subset of EGFR-mutant NSCLC patients with acquired resistance to EGFR inhibitors, either independently or in combination with genetic resistance mechanisms such as EGFR T790M(Sequist et al., 2011; Tulchinsky et al., 2019).